Lichen Planus is associated with which type of immune cells?

Lichen Planus is associated with which type of immune cells?

• A. B lymphocytes
• B. T lymphocytes
• C. Macrophages
• D. Eosinophils

Answer: (B)

Lichen Planus is primarily associated with T lymphocytes, specifically CD8+ T cells, which play a crucial role in the pathogenesis of this condition. In Lichen Planus, an inflammatory response mediated by these T cells leads to the destruction of the basal layer of the epithelium. As part of the immune response, activated T lymphocytes recognize and attack keratinocytes, resulting in the typical lesions seen in Lichen Planus. This condition is characterized by features such as a band-like infiltrate of T cells at the dermal-epidermal junction, indicating a cell-mediated immune response. The role of T lymphocytes highlights the involvement of adaptive immunity, distinguishing Lichen Planus from other dermatological conditions that may have a different immune profile. Understanding the specific immune response in Lichen Planus helps in crafting management strategies, including potential immunomodulatory treatments aimed at mitigating the activity of these T lymphocytes.

Lichen Planus is primarily associated with T lymphocytes, specifically CD8+ T cells, which play a crucial role in the pathogenesis of this condition. In Lichen Planus, an inflammatory response mediated by these T cells leads to the destruction of the basal layer of the epithelium. As part of the immune response, activated T lymphocytes recognize and attack keratinocytes, resulting in the typical lesions seen in Lichen Planus.

This condition is characterized by features such as a band-like infiltrate of T cells at the dermal-epidermal junction, indicating a cell-mediated immune response. The role of T lymphocytes highlights the involvement of adaptive immunity, distinguishing Lichen Planus from other dermatological conditions that may have a different immune profile.

Understanding the specific immune response in Lichen Planus helps in crafting management strategies, including potential immunomodulatory treatments aimed at mitigating the activity of these T lymphocytes.